KC Yamakawa joined SNBL CPC in 2004, serving as its first president until 2007. He has also served as CEO for Aderans America Holdings, Inc. and Genji, Inc. in the United States. Additionally, Mr. Yamakawa has a strong cross-cultural business background from holding positions including Director of Policy Planning at Cabinet Secretariat Office, Japanese Government, and First Secretary, Congressional Affairs Division, Washington DC, Embassy of Japan. With this extensive leadership and business background, Mr. Yamakawa is well suited to lead the North American region of SNBL, which includes SNBL USA and SNBL CPC.
“The decision to appoint Mr. Yamakawa as CEO to SNBL USA and SNBL CPC is part of SNBL’s global strategy to streamline operations as they relate to our range of preclinical to phase II clinical services and foster a unified process across our North America business units,” said Dr. Ryoichi Nagata, CEO and Chairman of the Board, SNBL Group. “I am very excited to have KC on board in his new role. His strong background in management and strategic planning will enable SNBL to facilitate its on-going efforts to support the drug development process from the North America region directly.”
About SNBL CPC, Inc.
SNBL Clinical Pharmacology Center (SNBL CPC) is a contract research organization (CRO) based in Baltimore, MD, focusing on Phase I/IIa clinical trials of drugs and medical devices. Its specialties are safety and tolerability testing, including dose ranging, single, multi-dose, ascending dose trials, drug interaction and special participant populations. SNBL CPC is dedicated to quality at all clinical phases and supports drug development and the advancement of medical technology to improve patient care. For additional information call 410.706.8877 or visit www.snbl-cpc.com.
About SNBL USA, Ltd.
Headquartered in Everett, WA, SNBL USA, Ltd. is a preclinical CRO that specializes in nonhuman primate (NHP) and small animal research. Study programs range from regulatory toxicology to customized study designs and disease models. Specialized programs include reproductive toxicology, safety pharmacology, immunotoxicology and carcinogenicity. Through a commitment to investment and excellence, SNBL USA strives to offer the biotechnology and pharmaceutical industries unparalleled quality in both science and service. For additional information call 425.407.0121 or visit www.snblusa.com.
SNBL CPC and SNBL USA are wholly-owned subsidiaries of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), one of the largest CROs in Japan. Established in 1957, SNBL currently employs approximately 2,000 team members worldwide and provides full service drug development capabilities ranging preclinical services through phase II clinical services.
